TCGA-UF-A71E-01A-31R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.343378995
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- CHOLESTEROL_HOMEOSTASIS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- MYC_TARGETS_V2+0.250
- MYC_TARGETS_V1+0.220
- P53_PATHWAY+0.220
- DNA_REPAIR+0.210
- MTORC1_SIGNALING+0.180
- HEDGEHOG_SIGNALING+0.160
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- IL6_JAK_STAT3_SIGNALING-0.430
- COMPLEMENT-0.400
- INFLAMMATORY_RESPONSE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- ANGIOGENESIS-0.370
- INTERFERON_GAMMA_RESPONSE-0.340
- KRAS_SIGNALING_UP-0.330
- COAGULATION-0.280
- ANDROGEN_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-AAS8-01A-11R-A405-07 | — | cohortSQ2 | 0.849 |
| 2 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.840 |
| 3 | SRR10900016 | — | — | 0.832 |
| 4 | SRR2779097 | — | — | 0.831 |
| 5 | TCGA-94-8490-01A-11R-2326-07 | — | cohortSQ2 | 0.830 |
| 6 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.828 |
| 7 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.827 |
| 8 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.827 |
| 9 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.824 |
| 10 | 87F9E756-60BB-435B-9A2D-211E89C182D9 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |